Australia markets closed
  • ALL ORDS

    6,986.80
    +4.10 (+0.06%)
     
  • ASX 200

    6,715.40
    +0.10 (+0.00%)
     
  • AUD/USD

    0.7707
    -0.0072 (-0.92%)
     
  • OIL

    52.11
    -1.46 (-2.73%)
     
  • GOLD

    1,826.20
    -25.20 (-1.36%)
     
  • BTC-AUD

    46,206.60
    -2,458.55 (-5.05%)
     
  • CMC Crypto 200

    681.79
    -53.35 (-7.26%)
     
  • AUD/EUR

    0.6379
    -0.0018 (-0.28%)
     
  • AUD/NZD

    1.0800
    +0.0030 (+0.28%)
     
  • NZX 50

    13,024.69
    -91.18 (-0.70%)
     
  • NASDAQ

    12,803.93
    -94.76 (-0.73%)
     
  • FTSE

    6,735.71
    -66.25 (-0.97%)
     
  • Dow Jones

    30,814.26
    -177.26 (-0.57%)
     
  • DAX

    13,787.73
    -200.97 (-1.44%)
     
  • Hang Seng

    28,573.86
    +77.00 (+0.27%)
     
  • NIKKEI 225

    28,519.18
    -179.08 (-0.62%)
     

Bluechiip Ltd (BCT.AX) Annual General Meeting - CEO's Presentation

·2-min read
Bluechiip Ltd
Bluechiip Ltd

Bluechiip Ltd (BCT.AX) Annual General Meeting - CEO's Presentation

Melbourne, Australia, Nov 27, 2020 - (ABN Newswire) - Bluechiip Ltd (ASX:BCT) has a world first, highly differentiated technology, with protected IP and a $200M growing target market, with very large adjacent markets.

The company has a Partner pipeline, with >35 developer kits sold, progressing to conversion.

The company is targeting scaled production to over 5 million chips per year, with a platform of readers & software commercially available now.

Bluechiip is well positioned with cash in bank, $6.6m (end September), and $1.5m due in R&D tax refund.

To view the presentation, please visit:
https://abnnewswire.net/lnk/9L0B56XW


About Bluechiip Ltd:


Bluechiip Ltd (ASX:BCT) has developed a wireless tracking solution for the healthcare and life science, security, defence and manufacturing industries which represents a generational change from current methods such as labels (hand-written and pre-printed), barcodes (linear and 2D) and microelectronic integrated circuit (IC)-based RFID (Radio Frequency Identification).

The unique tag is based on MEMS technology and contains no electronics. The tag can either be embedded or manufactured into a storage product, such as vials or bags. Easy identification, along with any associated information from the tag such as temperature can be detected by a reader, which can also sense the temperature of the tagged items. The traditional identification technologies have significant limitations. Whereas a barcode requires a visible tag or line-of-sight optical scan, bluechiip(R) technology does not. Unlike labels, barcodes and RFID, the bluechiip(R) technology can sense the temperature of each item a tag is attached to, or embedded in.

The bluechiip(R) technology has initial applications in the healthcare industry particularly those businesses which require cryogenic storage facilities (biobanks and biorepositories). bluechiip(R) offers the only technology that enables accurate and reliable tracking of products including stem cells, cord blood, and other biospecimens. In addition to functioning in extreme temperatures, the bluechiip(R) tracking solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

The bluechiip(R) technology has other healthcare applications in pathology, clinical trials and forensics. Several other key markets outside of healthcare include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Further information is available at http://www.bluechiip.com

Contact:

Lee Mitchell
Company Secretary
Bluechiip Limited
E: leem@nrlawyers.com.au
T: +61 (0) 3 9640 0400

Source:
Bluechiip Ltd

Copyright (C) 2020 ABN Newswire. All rights reserved.